SecSonar.com

Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Corcept Therapeutics Incorporated (CORT) is a Biotechnology company based in US with a market capitalization of $7.5B. Revenue grew 12.8% year-over-year and the company generated $141.8M in free cash flow. This page tracks CORT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 500 employees · IPO Apr 14, 2004

Valuation

Valuation & price

$56.37 · as of May 17, 2026 · -37.6% vs 52w high

67.9

P/E ratio

Latest-FY diluted EPS

11.50

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$90.21$61.30$32.39Jul 25Dec 25Jul 26Jul 7, 25$67.55Jul 9, 25$70.89Jul 11, 25$71.88Jul 15, 25$71.41Jul 17, 25$73.10Jul 21, 25$70.12Jul 23, 25$68.39Jul 25, 25$68.29Jul 29, 25$68.20Jul 31, 25$67.17Aug 4, 25$71.77Aug 6, 25$70.52Aug 11, 25$71.97Aug 13, 25$72.80Aug 15, 25$71.75Aug 19, 25$70.19Aug 21, 25$70.98Aug 25, 25$68.82Aug 27, 25$69.73Aug 29, 25$69.72Sep 3, 25$71.34Sep 5, 25$69.36Sep 9, 25$71.73Sep 11, 25$74.33Sep 16, 25$71.32Sep 18, 25$79.80Sep 22, 25$80.00Sep 24, 25$83.84Sep 26, 25$83.87Sep 30, 25$83.11Oct 2, 25$85.48Oct 6, 25$89.85Oct 8, 25$88.43Oct 10, 25$73.96Oct 14, 25$72.12Oct 16, 25$79.47Oct 21, 25$75.39Oct 23, 25$72.98Oct 27, 25$72.56Oct 29, 25$72.05Oct 31, 25$73.47Nov 4, 25$71.10Nov 6, 25$73.06Nov 10, 25$75.49Nov 12, 25$78.39Nov 14, 25$75.54Nov 18, 25$75.11Nov 20, 25$75.05Nov 25, 25$80.28Nov 28, 25$79.40Dec 2, 25$80.76Dec 4, 25$84.66Dec 8, 25$82.98Dec 10, 25$85.31Dec 12, 25$87.99Dec 16, 25$81.12Dec 18, 25$81.54Dec 22, 25$85.11Dec 24, 25$83.59Dec 29, 25$79.82Jan 2, 26$38.20Jan 6, 26$35.78Jan 8, 26$36.53Jan 12, 26$37.36Jan 14, 26$37.04Jan 16, 26$34.73Jan 21, 26$36.31Jan 23, 26$43.98Jan 27, 26$46.22Jan 29, 26$44.61Feb 2, 26$40.71Feb 4, 26$40.13Feb 9, 26$41.31Feb 11, 26$40.83Feb 13, 26$39.97Feb 18, 26$39.82Feb 20, 26$34.82Feb 24, 26$36.48Feb 26, 26$35.78Mar 2, 26$35.97Mar 4, 26$35.69Mar 6, 26$33.87Mar 10, 26$33.54Mar 12, 26$32.39Mar 17, 26$33.51Mar 19, 26$34.08Mar 23, 26$33.63Mar 25, 26$40.47Mar 27, 26$37.60Mar 31, 26$40.31Apr 2, 26$42.49Apr 7, 26$41.69Apr 9, 26$42.25Apr 13, 26$43.30Apr 15, 26$43.90Apr 17, 26$46.16Apr 22, 26$46.57Apr 24, 26$46.06Apr 28, 26$46.62Apr 30, 26$46.52May 4, 26$51.60May 6, 26$52.15May 8, 26$52.28May 12, 26$51.16May 14, 26$58.30May 18, 26$55.12May 20, 26$59.06May 22, 26$60.22May 28, 26$68.38Jun 1, 26$70.44Jun 3, 26$72.65Jun 5, 26$72.62Jun 9, 26$77.49Jun 11, 26$83.25Jun 15, 26$83.12Jun 17, 26$81.75Jun 22, 26$79.71Jun 24, 26$81.56Jun 26, 26$87.32Jul 2, 26$90.21
$32.1552-week range$90.32
Loading valuation history…

Fundamentals

Key fundamentals

$7.5B

Market cap

12.8%

Revenue growth (YoY)

98.3%

Gross margin

$141.8M

Free cash flow (USD)

-$366M

Net debt

Net cash position

0.6%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$81.3MFY 2017$159.2MFY 2018$251.2MFY 2019$306.5MFY 2020$353.9MFY 2021$366.0MFY 2022$401.9MFY 2023$482.4MFY 2024$675.0MFY 2025$761.4M
$81.3M$761.4M

Free cash flow by year

2016 → 2025

FY 2016$18.2MFY 2017$60.5MFY 2018$115.4MFY 2019$135.0MFY 2020$150.7MFY 2021$167.4MFY 2022$119.9MFY 2023$126.9MFY 2024$195.9MFY 2025$141.8M
$18.2M$141.8M

Gross margin by year

2021 → 2025

FY 202198.6%FY 202298.7%FY 202398.7%FY 202498.4%FY 202598.3%
98.6%98.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

12

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.7MMAHONEY DAVID L · Director · $1.7MJun 18, 2026Filing
  • Insider sellInsider Sell $832K · 10b5-1 PlanWILSON JAMES N · Director · $832KJun 18, 2026Filing
  • Insider sellInsider Sell $3.2M · 10b5-1 PlanMokari Atabak · Chief Financial Officer · $3.2MJun 17, 2026Filing
  • 8-K eventNew Drug Application ResubmissionJun 17, 2026Filing
  • Insider sellInsider Sell $1.4M · 10b5-1 PlanGuyer William · Chief Development Officer · $1.4MJun 4, 2026Filing
  • Insider sellInsider Sell $2.8M · 10b5-1 PlanMokari Atabak · Chief Financial Officer · $2.8MJun 3, 2026Filing
  • Insider sellInsider Sell $1.8M · 10b5-1 PlanMaduck Sean · See Remarks · $1.8MJun 3, 2026Filing
  • 8-K eventDOJ Declines InterventionJun 3, 2026Filing
  • Insider sellInsider Sell $895K · 10b5-1 PlanBELANOFF JOSEPH K · Director, Chief Executive Officer · $895.3KJun 2, 2026Filing
  • Insider sellInsider Sell $4.9M · 10b5-1 PlanMaduck Sean · See Remarks · $4.9MMay 29, 2026Filing

Questions

Frequently asked questions

What is Corcept Therapeutics Incorporated's market cap?

Corcept Therapeutics Incorporated (CORT) has a market capitalization of $7.5B.

What is CORT's P/E ratio?

CORT trades at a price-to-earnings ratio of 67.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is CORT's price-to-book (P/B) ratio?

CORT trades at 11.50 times book value per share.

Are insiders buying CORT stock?

SEC Form 4 filings show no open-market insider buys at Corcept Therapeutics Incorporated in the last 90 days (12 sells).

Same arena

Related companies in Biotechnology

PRAX

Praxis Precision Medicines, Inc.

$7.2B

ALKS

Alkermes plc

$7.1B

IBRX

ImmunityBio, Inc.

$7.9B

HALO

Halozyme Therapeutics, Inc.

$8B

TECH

Bio-Techne Corporation

$8.1B

KYMR

Kymera Therapeutics, Inc.

$6.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.